ValeriePrattIsraelDO(She/Her)

PubMed

• 42 citations
  Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation.
  Ilene C. Weitz, Valerie Israel, James Waisman, Cary A. Presant, Leanne Rochanda
  Thrombosis and Haemostasis. 2002-08-01
• 916 citations
  Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A So...
  Karen Kelly, John Crowley, Paul A. Bunn, Cary A. Presant, Patra K. Grevstad
  Journal of Clinical Oncology. 2001-07-01
• 15 citations
  Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma
  Mark A. Socinski, Alan B. Sandler, Valerie K. Israel, Heidi H. Gillenwater, Langdon L. Miller
  Cancer. 2002-10-01

Journal Articles

• Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III nonsmall-cell lung can...  
  Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V, Lara P, Wilder R, Ryu J, Doroshow J, J Clin Oncol, 1/15/2001
• Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial  
  Lara PN Jr, Gandara DR, Longmate J, Gumerlock PH, Lau DH, Edelman MJ, Gandour-Edwards R, Mack PC, Israel V, Raschko J, Frankel P, Perez EA, Lenz HJ, Doroshow JH, Cancer Chemother Pharmacol, 1/1/2001
• Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC  
  Natale RB, Socinski M, Sandler A, Israel VP, Miller L, Oncology, 1/1/2000
• MDR1 gene expression in primary and advanced breast cancer  
  Yang X, Uziely B, Groshen S, Lukas J, Israel V, Russell C, Dunnington G, Formenti S, Muggia F, and Press M, Laboratory Investigation, 1/1/1999
• Tamoxifen associated venous thrombosis and activated protein C resistance due to factor V Leiden  
  Weitz IC, Israel VK, Liebman HA, Cancer, 1/1/1997
• Intraperitoneal 5-fluoro-2'deoxyuridine and (s)-leucovorin for disease predominately confined to the abdominal cavity: A pharmacokinetic and toxicity study  
  Israel V, Chun J, Muggia F, et al, Cancer Chemother and Pharm, 1/1/1995
• Paclitaxel 3-hour infusion given alone and combined with carboplatin: Preliminary results of dose escalation trials  
  Muggia FM, Vafai D, Natale R, Israel V, Zaretsky S, McRae A, Rogers M, Jeffers S, Sem Oncol, 1/1/1995
• Join now to see all

Books/Book Chapters

• Difficult Problems in Surgical Oncology 
  Chapter: Management of high risk breast cancer 
  Israel VK, Spicer DVEditors: H Silberman and AW Silberman.Arnold/Hodder Publishers, Hodder Headline Group, London, UK2002
• Tumor Board Case Management 
  Chapter: Recurrent Mediastinal Nonseminomatous Germ Cell Malignancy 
  Page 301 - 306Israel VK, Russell CA, Dolkar D, Streeter OEditors: DP Winchester, et al.Lippincott-Raven1997
• Clin Oncol 
  Chapter: Bladder Cancer 
  Page 1419 - 1438Israel VK, Natale RB, Skinner DGEditors: Abelloff.1995
• Medical Oncology 
  Chapter: Esophageal Cancer 
  Page 649 - 670Leichman L, Israel VEditors: Calibresi.Edition 2nd,1993
• Current Gastroenterology 
  Chapter: Advances in Chemotherapy in Gastrointestinal Malignancies 
  Page 205 - 223Leichman L, Israel VEditors: G. Gitnick.1992
• Join now to see all

Abstracts/Posters

• Phase I study of biweekly paclitaxel and carboplatin plus GCSF
  Israel V, Garcia AA, , Russell CA, Dimery I, Rogers M, Angeles A, Kutsch K, Jeffers S, Muggia FM, PASCO, 1/1/1999
• Phase I study of doxil (liposomal doxorubicin) in combination with paclitaxel
  Israel VK, Jeffers S, Bernal G, Rueda G, Roman L, Roma CP, Rosales R, Amantea M, and Muggia FM, PASCO, 1/1/1998
• Liposomal doxorubicin (doxil): Prospects for its integration into treatment of solid tumors
  Muggia FM, Israel V, Formenti S, Garcia A, Safra T, Jeffers S, Kempf R, PASCO, 1/1/1997
• Hydroxyurea IV 72-hour infusion during intraperitoneal floxuridine and leucovorin: pharmacological/clinical correlates
  Koda R, Parimoo D, Spears CP, Israel V, Jeffers S, Rogers M, Leichman L, Leichman CG, Pujari M, Muggia F, AACR, 1/1/1996
• Paclitaxel (Taxol) induces transient increase in serum lipids: A consequence of inhibition of receptor recycling?
  Israel V, Hamm-Alvarez S, Rogers M, Jeffers S, Muggia F, AF-CR, 1/1/1995
• Intraperitoneal floxuridine and leucovorin with simultaneous 72h hydroxyurea infusion: pharmacology and tolerance
  Muggia F, Israel V, Pujari M, Spears CP, Leichman L, Leichman CG, Jeffers S, Rogers M, Koda R, AACR, 1/1/1995
• Phase I/II trial of combination carboplatin and Taxol in advanced non small cell lung cancer
  Israel VK, Zaretsky S, Natale RB, ASCO, 1/1/1995
• Intraperitoneal 5-fluoro-2'deoxyuridine results of tree sequential trials without and with leucovorin modulation
  Israel V, Muggia F, Jeffers S, et al, 8th NCI -EORTC Symposium on New Drugs in Cancer Therapy, 1/1/1994
• Phase I/II trial of combination carboplatin and Taxol in advanced non-small cell lung cancer
  Israel V, Natale R, Zaretsky S, Proc ASCO, 1/1/1994
• Giant cell cancer of the lung and leukocytosis: Search for humoral factors
  Parimoo D, Israel V, Muggia F, et al, 7th World Conference on Lung Cancer, 1/1/1994
• Join now to see all